AR and posterior cortical atrophy: FDA approval and clinical use of high-affinity AR pathway inhibitors, such as enzalutamide, abiraterone, and apalutamide, in the past decade, have greatly improved care for patients with PCa and substantially prolonged patients’ lives (28).